Business PR Newswire Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 rvrisingnetwork December 3, 2025 Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau…
Business PR Newswire LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025” rvrisingnetwork October 15, 2025 TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo…